Fig. 5

SNHG1 binds with EZH2 leading to epigenetically silencing of KLF2. a RIPs experiments for EZH2 were performed and the coprecipitated RNA was subjected to qRT-PCR for SNHG1 in PDLSCs with or without OM treatment. *p < 0.05 versus IgG; ^#p < 0.05 versus non-induced. b The protein levels EZH2, KLF2, and H3K27me3 were analyzed at day 14 of osteogenic differentiation after indicated treatment with GAPDH as a control. c RIPs experiments for EZH2 were performed and the coprecipitated RNA was subjected to qRT-PCR for SNHG1 in PDLSCs after indicated treatment along with OM treatment. d ChIP assays were performed to detect EZH2 and H3K27me3 occupancy in the KLF2 promoter region. e ALP staining of PDLSCs at day 14 of osteogenic differentiation after indicated treatment. f ALP activity was measured at day 14 of osteogenic differentiation after indicated treatment. g Alizarin Red staining of PDLSCs at day 14 of osteogenic differentiation after indicated treatment and quantification was shown at right. h Proposed model of SNHG1 regulating KLF2 expression to inhibit osteogenic differentiation of PDLSCs. *p < 0.05 versus vector; ^#p < 0.05 versus SNHG1